Macrophage adaptation in airway inflammatory resolution.
Bacterial and viral infections (exacerbations) are particularly problematic in those with underlying respiratory disease, including post-viral infection, asthma, chronic obstructive pulmonary disease and pulmonary fibrosis. Patients experiencing exacerbations tend to be at the more severe end of the disease spectrum and are often difficult to treat. Most of the unmet medical need remains in this patient group. Airway macrophages are one of the first cell populations to encounter airborne pathogens and, in health, exist in a state of reduced responsiveness due to interactions with the respiratory epithelium and specific factors found in the airway lumen. Granulocyte-macrophage colony-stimulating factor, interleukin-10, transforming growth factor-β, surfactant proteins and signalling via the CD200 receptor, for example, all raise the threshold above which airway macrophages can be activated. We highlight that following severe respiratory inflammation, the airspace microenvironment does not automatically re-set to baseline and may leave airway macrophages more restrained than they were at the outset. This excessive restraint is mediated in part by the clearance of apoptotic cells and components of extracellular matrix. This implies that one strategy to combat respiratory exacerbations would be to retune airway macrophage responsiveness to allow earlier bacterial recognition.
Manchester Collaborative Centre for Inflammation Research, Manchester University, Core Technology Facility, Manchester, UK.
Manminder
M
Kaur
Manchester Collaborative Centre for Inflammation Research, Manchester University, Core Technology Facility, Manchester, UK.
Thomas
T
Bell
Manchester Collaborative Centre for Inflammation Research, Manchester University, Core Technology Facility, Manchester, UK.
Samira
S
Salek-Ardakani
Manchester Collaborative Centre for Inflammation Research, Manchester University, Core Technology Facility, Manchester, UK tracy.hussell@manchester.ac.uk.
Tracy
T
Hussell
D000222:Adaptation, Physiological; D000818:Animals; D060833:Cellular Microenvironment; D054884:Host-Pathogen Interactions; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology / Q000378:metabolism; D008168:Lung / Q000276:immunology* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology / Q000821:virology; D008262:Macrophage Activation; D016676:Macrophages, Alveolar / Q000276:immunology* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology / Q000821:virology; D010641:Phenotype; D018410:Pneumonia, Bacterial / Q000175:diagnosis / Q000276:immunology* / Q000378:metabolism / Q000382:microbiology; D011024:Pneumonia, Viral / Q000175:diagnosis / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D018570:Risk Assessment; D012307:Risk Factors; D015398:Signal Transduction
D018836:Inflammation Mediators